

1

2

3

4 Tolerability of Long-acting Diquafosol Ophthalmic Solution

5 as per Tear Film and Meibomian Glands Findings

6

7 Reiko Arita<sup>1,2\*</sup>, Shima Fukuoka<sup>2,3</sup>, Minako Kaido<sup>2,4</sup>

8

9 <sup>1</sup> Itoh Clinic, Saitama, Japan

10 <sup>2</sup> Lid and Meibomian Gland Working Group, Saitama, Japan

11 <sup>3</sup> Omiya Hamada Eye Clinic, Saitama, Japan

12 <sup>4</sup> Wada Eye Clinic, Chiba, Japan

13

14 **\*Corresponding author**

15 Email: [ritoh@za2.so-net.ne.jp](mailto:ritoh@za2.so-net.ne.jp) (RA)

16

17 **Short Title:** Tolerability of DQS-LX

18

## 19 **Abstract**

20 Long-acting diquafosol (DQS) ophthalmic solution (DQS-LX) has significant advantages  
21 regarding patient adherence owing to the reduced frequency of required eye drops;  
22 however, some patients prefer conventional DQS over DQS-LX. Herein, to clarify the  
23 characteristics of patients according to their preference for ophthalmic solutions, dry eye  
24 (DE) and meibomian gland (MG) findings were retrospectively investigated. This study  
25 enrolled 341 patients with DE (mean age,  $62.1 \pm 11.7$  years) treated at the Itoh Clinic  
26 between November 8, 2022, and July 31, 2023, who switched from DQS to DQS-LX.  
27 Patients were divided into two groups: those who continued DQS-LX administration  
28 (DQS-LX group) and those who wished to revert to conventional DQS (DQS group).  
29 Data regarding subjective symptoms assessed using the Standard Patient Evaluation of  
30 Eye Dryness (SPEED) questionnaire, tear film breakup time (BUT), tear meniscus height  
31 (TMH), corneal and conjunctival fluorescein staining (CFS), conjunctival  
32 hyperemia/papilla, meiboscore, plugging, vascularity, meibum grade, and Schirmer's  
33 score at the time of DQS-LX switch were evaluated. Of the 341 patients, 31 (9.1%)  
34 wished to revert to conventional DQS. In total, 32 eyes of 16 patients in the DQS group  
35 and 64 eyes of 32 patients in the DQS-LX group—for whom complete data were  
36 available—were included in the analysis. Compared with the DQS group, the DQS-LX

37 group had significantly higher SPEED scores, shorter BUTs, lower TMHs, greater CFS  
38 findings, larger meibum grades (all  $P < 0.001$ ), lower Schirmer scores ( $P = 0.008$ ), and  
39 more pluggings ( $P = 0.001$ ) than the DQS group. More allergic conjunctivitis-related  
40 complications were observed in the DQS group ( $P = 0.034$ ). In conclusion, patients with  
41 low tear film volume and DE complicated by moderate or severe MG dysfunction  
42 preferred DQS-LX, while those with allergic findings preferred conventional DQS.

43

## 44 **Introduction**

45 Tear film instability, in which an imbalance in the ocular surface tear film  
46 deteriorates its stability and regularity, is an important cause of dry eye (DE). The P2Y<sub>2</sub>  
47 receptor agonist diquafosol tetrasodium (DQS) was developed as an eye drop to improve  
48 tear film stability by stimulating tear and mucin secretion [1, 2]. The introduction of this  
49 ophthalmic solution has led to significant changes in treatment strategies for patients with  
50 DE. Many reports have shown the efficacy of DQS ophthalmic solutions in improving  
51 corneal staining, stabilizing tear fluid film, and relieving DE symptoms [3-6]. As P2Y<sub>2</sub>  
52 receptors are also present in meibomian glands, a DQS-induced increase in the lipid layer  
53 has been reported in several studies [7-12]. DQS comprehensively targets the aqueous,  
54 mucin, and lipid layers. However, DQS ophthalmic solutions must be applied six times

55 per day to keep the ocular surface moist, which reduces patient compliance. Uchino et al.  
56 reported that only 10.2% of participants applied eye drops at the frequency described in  
57 the package insert [13].

58         Recently, a new long-acting formulation of DQS ophthalmic solution (DQS-LX)  
59 was developed [14] through the addition of polyvinylpyrrolidone (PVP), which reduced  
60 the required frequency of eye drops to three times a day. While several patients who were  
61 prescribed DQS switched to DQS-LX, some preferred DQS [15, 16]. Previous studies  
62 have reported changes in subjective symptoms, fluorescein tear film breakup time  
63 (FBUT), and fluorescein staining findings after switching from DQS to DQS-LX [15, 16].  
64 However, no comprehensive studies have investigated ocular surface parameters,  
65 including meibomian gland-related parameters and allergic conjunctivitis-related  
66 complications.

67         Herein, we compared ocular surface parameters, including the meibomian gland  
68 findings, related to the parameters and condition of the tarsal conjunctiva, to identify  
69 differences between patients who were on conventional DQS and switched to DQS-LX,  
70 those who were satisfied with DQS-LX and wished to continue DQS-LX, and those who  
71 wished to revert to DQS.

72

## 73 **Materials and Methods**

74 This retrospective cohort study was approved by the Institutional Review Board  
75 of the Itoh Clinic and adhered to the tenets of the Declaration of Helsinki (Registration  
76 ID: IRIN2023-0909). Informed consent was obtained from all the participants. This  
77 study was registered with the University Hospital Medical Information Network  
78 (Registration ID: UMIN000054378). There was no contact with patients or legal  
79 guardians as all data was obtained by study investigators through patient identification  
80 numbers on the electronic health system and subsequently fully anonymized to ensure  
81 patient confidentiality.

82

## 83 **Participants**

84 This study included 341 DE patients ( $62.1 \pm 11.7$  years) treated at the Itoh  
85 Clinic between November 8, 2022, and July 31, 2023 who switched from DQS to DQS-  
86 LX. Data of those who continued DQS-LX for at least 1 month (DQS-LX group) and  
87 those who wished to revert to conventional DQS within 3 months (DQS group) were  
88 retrospectively compared. Patients using eye drops or oral medications other than DQS  
89 were included in the current study, and other treatments remained unchanged, except for  
90 the switchover from DQS to DQS-LX. Both eyes of patients were included in this study.

91 Patients who had used DQS for less than 3 months, used DQS-LX for less than 1 month,  
92 had punctal plugs, wore contact lenses, used anti-glaucoma eye drops, undergone eye  
93 surgery within 3 months, and could not provide consent were excluded.

94

## 95 **Clinical Assessment**

96 Clinical assessment items were measured at the time of the DQS-LX  
97 switchover. Symptoms were assessed using the Standard Patient Evaluation of Eye  
98 Dryness (SPEED) validated questionnaire (scale, 0–28) [17,18]. Tear meniscus height  
99 (TMH) was quantitatively measured using an IDRA (SBM Sistemi, Torino, Italy) [17,  
100 18]. Lid margin abnormalities (plugging of the meibomian gland orifices and  
101 vascularity of lid margins) [19], FBUT, corneal and conjunctival fluorescein staining  
102 (CFS) [20], and meibum grade (0-3) [21] were evaluated using slit-lamp microscopy.  
103 FBUT was measured after instilling 1 µl of preservative-free 1% sodium fluorescein  
104 into the conjunctival sac using a micropipette. CFS was scored on a scale of 0–9 points  
105 as previously described [20]. Conjunctival hyperemia and papillae were observed.  
106 Morphological changes in the meibomian glands were assessed based on the  
107 meiboscore (0-6) [22] as determined by noninvasive meibography. Tear fluid  
108 production was measured using Schirmer’s test without anesthesia [23].

109

## 110 **Statistical Analysis**

111 Data are presented as means  $\pm$  standard deviation (SD). The Shapiro–Wilk test  
112 revealed the non-normal distribution of the data ( $P < 0.05$ ); thus, nonparametric tests were  
113 used. The Fisher’s exact test was used to compare categorical variables between the DQS  
114 and DQS-LX groups. The Mann–Whitney  $U$  test was used to compare continuous  
115 variables between the two groups. We performed a post-hoc power analysis for the  
116 SPEED score, TMH, and FBUT. For the SPEED score, the mean difference between the  
117 two groups was 3.8, with a corresponding SD of 6.2; for the TMH, the mean difference  
118 was 0.04 with an SD of 0.05; and for the FBUT, the mean difference was 0.49 with an  
119 SD of 1.23. These changes were calculated using the data from 96 eyes of 48 patients.  
120 The power ( $1 - \beta$ ) was  $> 0.95$  at the level of  $\alpha = 0.05$  for the SPEED score, TMH, and  
121 FBUT, and the sample size of this study was sufficient. Statistical analyses were  
122 performed using JMP Pro version 17 software (SAS, Cary, NC, USA). All statistical tests  
123 were two-sided, and a  $P$ -value  $< 0.05$  was considered statistically significant.

124

## 125 **Results**

### 126 **Demographics of the Study Population**

127 Of 341 patients, 31 (9.1%) wished to revert to conventional DQS. In total 48  
128 (14.1%) out of 341 patients had adequate records and were eligible for further analyses.  
129 The DQS group included 32 eyes of 16 patients ( $64.1 \pm 12.6$  years) and the DQS-LX  
130 group included 64 eyes of 32 patients ( $61.1 \pm 11.2$  years) (Table 1). The concomitant  
131 therapies and comorbidities at the time of the switchover to DQS-LX are shown in Tables  
132 1 and 2. Regarding complications, allergic conjunctivitis was significantly more common  
133 in the DQS group ( $P = 0.034$ ) (Table 1), and significantly more patients in the DQS group  
134 used anti-allergic eye drops ( $P = 0.034$ ) (Table 2). Significantly more patients in the DQS-  
135 LX group used 0.1% fluorometholone eye drops ( $P = 0.012$ ) (Table 2). Significantly more  
136 patients in the DQS-LX group used azithromycin eye drops ( $P = 0.002$ ) and had a  
137 significantly higher history of intense pulsed light treatment ( $P = 0.013$ ) (Table 2).

138

139 **Table 1. Baseline characteristics of patients in the DQS and the DQS-LX groups.**

<b>Characteristic</b>	<b>DQS group</b>	<b>DQS-LX group</b>	<b><i>P</i></b>
	<b>(<i>n</i> = 16)</b>	<b>(<i>n</i> = 32)</b>	
<b>Age (years), mean <math>\pm</math> SD (range)</b>	64.1 $\pm$ 12.6 (35-87)	61.1 $\pm$ 11.2 (39-83)	0.36
<b>Sex (male/female)</b>	3 (19%)/13 (81%)	6 (19%)/26 (81%)	1



<b>Allergic conjunctivitis</b>	11 (69%)	11 (34%)	0.034*
<b>Collagen disease</b>	2 (13%)	8 (25%)	0.46
<b>Sjögren syndrome</b>	2 (13%)	5 (16%)	1
<b>Rheumatoid arthritis</b>	0 (0%)	3 (9%)	0.54
<b>SLK</b>	0 (0%)	3 (9%)	0.54
<b>History of cataract surgery</b>	3 (19%)	4 (13%)	0.67

140 *P*-values were obtained using the Mann–Whitney *U* test or Fisher’s exact test. \**P* < 0.05

141 (Fisher’s exact test).

142 SLK, superior limbic keratoconjunctivitis; SD, standard deviation.

143

144 **Table 2. Concomitant therapies at the switchover from DQS to DQS-LX in the DQS**

145 **and DQS-LX groups.**

<b>Therapy</b>	<b>DQS group</b>	<b>DQS-LX group</b>	<b><i>P</i></b>
	<b>(<i>n</i> = 16)</b>	<b>(<i>n</i> = 32)</b>	
<b>Eye drops for dry eye</b>	2 (13%)	10 (31%)	0.29
<b>Rebamipide UD</b>	2 (13%)	7 (22%)	0.70
<b>Sodium hyaluronate 0.1%</b>	0 (0%)	3 (9%)	0.54
<b>Sodium hyaluronate Mini 0.3%</b>	0 (0%)	1 (3%)	1.0

<b>Anti-allergic eye drops</b>	11 (69%)	11 (34%)	0.034*
<b>Epinastine 0.05%</b>	1 (6%)	0 (0%)	0.33
<b>Epinastine 0.1%</b>	9 (56%)	10 (31%)	0.12
<b>Olopatadine</b>	1 (6%)	1 (3%)	1.0
<b>Azithromycin</b>	0 (0%)	14 (44%)	0.002*
<b>Fluorometholone 0.1%</b>	5 (31%)	23 (72%)	0.012*
<b>IPL</b>	3 (19%)	19 (59%)	0.013*

---

146 \* $P < 0.05$ .  $P$ -values were obtained using the Fisher's exact test.

147 Rebamipide UD, rebamipide (Mucosta®) ophthalmic suspension UD2% (unit dose);

148 Sodium hyaluronate 0.1%, purified sodium hyaluronate (Hyalein®) ophthalmic solution

149 0.1%; Sodium hyaluronate Mini 0.3%, purified sodium hyaluronate single-dose unit

150 (Hyalein® Mini) ophthalmic solution 0.3%; Epinastine 0.05%, epinastine hydrochloride

151 (Alesion®) ophthalmic solution 0.05%; Epinastine 0.1%, epinastine hydrochloride

152 (Alesion® LX) ophthalmic solution 0.1%; Azithromycin, azithromycin hydrate

153 (Azimycin®) ophthalmic solution 1%; Fluorometholone 0.1%, fluorometholone

154 (Flumetholon®) ophthalmic suspension 0.1%; IPL, intense pulsed light therapy.

155

156 **Subjective Symptoms and Ocular Surface Parameters at the**  
157 **Time of the Switchover**

158 Subjective symptoms and tear film parameters at the time of the switchover are  
159 shown in Table 3. Compared with the DQS group, the DQS-LX group had higher SPEED  
160 scores, lower TMHs, shorter FBUTs, greater CFS findings, larger meibum grades (all  $P$   
161  $< 0.001$ ), lower Schirmer scores ( $P = 0.008$ ), and more pluggings ( $P = 0.001$ ).  
162 Meiboscores and vascularity did not differ significantly between the two groups ( $P = 0.26$   
163 and  $0.21$ , respectively) (Table 3).

164

165 **Table 3. Comparison of subjective symptoms and ocular surface parameters at the**  
166 **switchover from DQS to DQS-LX in the DQS and DQS-LX groups.**

Characteristic	DQS group	DQS-LX group	$P$
<b>SPEED (0-28)</b>	8.1 ± 4.2	16.1 ± 6.9	<0.001**
<b>TMH (mm)</b>	0.24 ± 0.05	0.15 ± 0.04	<0.001**
<b>Plugging (0-3)</b>	2.1 ± 0.9	2.6 ± 0.7	0.001*
<b>Vascularity (0-3)</b>	1.3 ± 1.1	1.6 ± 1.0	0.21
<b>FBUT (sec)</b>	3.3 ± 1.1	2.3 ± 1.3	<0.001**
<b>CFS (0-9)</b>	0.3 ± 0.4	1.9 ± 2.3	<0.001**

<b>Presence of conjunctival hyperemia and papillae (n (%))</b>	11 (69%)	11 (34%)	0.034†
<b>Meibum grade (0-3)</b>	1.3 ± 0.7	2.0 ± 0.6	<0.001**
<b>Meiboscore (0-6)</b>	2.5 ± 1.3	2.9 ± 1.2	0.26
<b>Schirmer's test (mm)</b>	5.9 ± 4.8	3.9 ± 3.6	0.008*

---

167 DQS group ( $n = 16$ ) and DQS- LX group ( $n = 32$ ) for SPEED score; DQS group ( $n = 32$   
168 eyes) and DQS- LX group ( $n = 64$  eyes) for the other parameters. Data are presented as  
169 means ± SD unless noted otherwise. \* $P < 0.05$  and \*\* $P < 0.001$  (the Mann–Whitney  $U$   
170 test). † $P < 0.05$  (the Fisher’s exact test).

171 SPEED, Standardized Patient Evaluation of Eye Dryness; TMH, tear meniscus height;  
172 FBUT, breakup time of the tear film with fluorescein; CFS, corneal and conjunctival  
173 fluorescein staining; SD, standard deviation.

174

175 The reasons for reverting to DQS after switching to DQS-LX were stickiness in  
176 the eye in the morning ( $n = 13$ , 3.8%), increased eye discharge ( $n = 12$ , 3.5%), itchiness  
177 after eye drops ( $n = 8$ , 2.3%), wanting to eye drops use more than three times per day ( $n$   
178 = 4, 1.2%), and eye irritation ( $n = 3$ , 0.8%).

179

## 180 **Discussion**

181           The study demonstrated that approximately 90% of patients who were  
182 prescribed DQS could tolerate the change to DQS-LX. Furthermore, patients with more  
183 severe DE and those with DE complicated by MG dysfunction could tolerate DQS-LX,  
184 whereas those with DE complicated by allergic conjunctivitis could not.

185           The actions of DQS-LX include the following: (i) temporary coating of the  
186 ocular surface due to the increased viscosity of the ophthalmic solution caused by PVP,  
187 (ii) improved adherence due to the reduced frequency of required eye drops, (iii) mucin  
188 and aqueous layer secretion effects of DQS, (iv) an increased lipid layer due to lipid  
189 secretion effects, and (v) reduced friction. As DQS and DQS-LX both influence  
190 aqueous, mucin, and lipid layers, the efficacy of the eye drops in patients with severe  
191 DE may particularly be influenced by the other aforementioned factors. An increase in  
192 the lipid layer was observed for DQS in previous reports [7, 8, 11, 24]; however, DQS-  
193 LX is considered to facilitate the contact between the liquid layer and the lipid reservoir,  
194 increasing the amount of lipids in the tear film. Moreover, the improved adherence may  
195 likely lead to better results regarding mucin and water secretion effects and the lipid  
196 layer for DQS-LX than for DQS.

197           Herein, the tolerability for DQS-LX was very good (> 90%). The group with  
198 better tolerability to DQS-LX had worse tear films, meibomian gland parameters, and  
199 subjective symptoms at the time of the switchover than the group with lesser tolerability  
200 to DQS-LX. Patients with moderate-to-severe DE and DE complicated by MG  
201 dysfunction tended to tolerate DQS-LX well. We speculated that the increased viscosity  
202 of DQS-LX due to the addition of the PVP resulted in a better coating of the ocular  
203 surface, reduction in ocular surface irritation, improvement in tear fluid stability, and  
204 improvements in corneal and conjunctival epithelial damage. It has also been suggested  
205 that DQS-LX may be longer-lasting in patients with DE with concomitant MG  
206 dysfunction because of its lipid-increasing effect on the tear film, which decreases  
207 friction between the eyelid and cornea, facilitates eyelid opening, and decreases the  
208 evaporation of tear fluid.

209           It has been suggested that patients with DE and allergic conjunctivitis may  
210 have difficulty tolerating DQS-LX because PVP, which is added to DQS-LX as a  
211 viscosifying agent, increases the residence time of allergens on the ocular surface and  
212 exacerbates the symptoms (itching).

213           Ishikawa et al.[15] reported that 94.4% (51/54) of patients preferred DQS-LX.  
214 However, therein[15], only patients with relatively mild disease who used DQS and

215 DQS-LX as a single therapy were included. To represent patients with DE in a real  
216 clinical scenario, we included patients who were receiving concomitant DE  
217 medications, such as rebamipide or sodium hyaluronate eye drops, as well as patients  
218 with a history of intense pulsed light treatment. Although there were differences in  
219 disease severity among participants, the results were similar. In a report by Kaido and  
220 Arita [16], 84.8% (46/56) of patients had an FBUT of  $2.9 \pm 1.9$  s and a similar DE  
221 severity; however, the mean age of the cohort was  $74.0 \pm 10.4$  years, which was older  
222 than that in our study cohort. With aging, tear fluid clearance is expected to decrease  
223 owing to increased complications of conjunctival chalasis [25] and reduced blinking  
224 ability [26]. When these complications occur in older patients, the high viscosity of  
225 DQS-LX may result in ineffective diffusion on the ocular surface and excessive  
226 retention of ophthalmic fluid in the lower eyelid. The stability of the tear film and  
227 improvement of corneal flaws may be affected, making eye drops more difficult to  
228 apply and less successful in covering the ocular surface.

229 The reasons for not tolerating the DQS-LX were as follows: dislike of sticky eyelids upon  
230 waking, concern regarding large amounts of eye discharge, itchy eyes, desire for frequent  
231 application, and eye irritation. These results are similar to those of previous reports [14,  
232 15]. However, these percentages were similar to the results of Ishikawa et al.[15], but less

233 than those reported by Kaido and Arita.[16] The difference in the proportion of side  
234 effects may be related to age differences among the subjects[16]. The Dry Eye  
235 Assessment and Management (DREAM) study[27] reported that as age increased, corneal  
236 and conjunctival staining findings increased, BUT shortened, symptoms worsened, and  
237 tear osmolarity increased; the older age of the previous study's cohort [16] likely  
238 contributed to the higher rate of complaints regarding ocular symptom [28].

239 The retrospective nature of this study presents a limitation because it examined  
240 the tolerability of DQS-LX in patients who were already prescribed DQS. Future  
241 prospective studies are required to determine the characteristics of patients who prefer  
242 DQS over DQS-LX and vice versa.

243

## 244 **Conclusion**

245 High-viscosity DQS-LX ophthalmic solution is well-tolerated in patients with  
246 DE. Patients with moderate or severe DE and MG dysfunction tended to prefer DQS-LX,  
247 whereas those with DE and allergic findings preferred conventional DQS.

248

249



## 250 **References**

251

252 1. Lau OC, Samarawickrama C, Skalicky SE. P2Y2 receptor agonists for the  
253 treatment of dry eye disease: a review. Clin Ophthalmol. 2014;8:327-34. Epub  
254 2014/02/11. doi: 10.2147/OPTH.S39699. PubMed PMID: 24511227; PubMed Central  
255 PMCID: PMC3915022.

256 2. Keating GM. Diquafosol ophthalmic solution 3 %: a review of its use in dry eye.  
257 Drugs. 2015;75(8):911-22. Epub 2015/05/15. doi: 10.1007/s40265-015-0409-7. PubMed  
258 PMID: 25968930.

259 3. Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, et al.  
260 Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium  
261 (INS365) ophthalmic solution for the treatment of dry eye. Cornea. 2004;23(8):784-92.  
262 Epub 2004/10/27. doi: 10.1097/01.ico.0000133993.14768.a9. PubMed PMID: 15502479.

263 4. Bremond-Gignac D, Gicquel JJ, Chiambaretta F. Pharmacokinetic evaluation of  
264 diquafosol tetrasodium for the treatment of Sjogren's syndrome. Expert Opin Drug Metab  
265 Toxicol. 2014;10(6):905-13. Epub 2014/05/07. doi: 10.1517/17425255.2014.915026.  
266 PubMed PMID: 24797483.

- 267 5. Shigeyasu C, Yamada M, Akune Y, Fukui M. Diquafosol for Soft Contact Lens  
268 Dryness: Clinical Evaluation and Tear Analysis. *Optometry and vision science : official*  
269 *publication of the American Academy of Optometry.* 2016;93(8):973-8. Epub 2016/04/27.  
270 doi: 10.1097/OPX.0000000000000877. PubMed PMID: 27115327.
- 271 6. Jeon HS, Hyon JY. The Efficacy of Diquafosol Ophthalmic Solution in Non-  
272 Sjogren and Sjogren Syndrome Dry Eye Patients Unresponsive to Artificial Tear. *J Ocul*  
273 *Pharmacol Ther.* 2016;32(7):463-8. Epub 2016/06/14. doi: 10.1089/jop.2015.0081.  
274 PubMed PMID: 27294831.
- 275 7. Fukuoka S, Arita R. Increase in tear film lipid layer thickness after instillation of  
276 3% diquafosol ophthalmic solution in healthy human eyes. *The ocular surface.*  
277 2017;15(4):730-5. Epub 2017/04/02. doi: 10.1016/j.jtos.2017.03.005. PubMed PMID:  
278 28363586.
- 279 8. Fukuoka S, Arita R. Tear film lipid layer increase after diquafosol instillation in  
280 dry eye patients with meibomian gland dysfunction: a randomized clinical study. *Sci Rep.*  
281 2019;9(1):9091. Epub 2019/06/27. doi: 10.1038/s41598-019-45475-7. PubMed PMID:  
282 31235821; PubMed Central PMCID: PMC6591396 Japan). S.F. has received  
283 financial support from Santen Pharmaceutical Co. Ltd. R.A. is a consultant for Kowa Co.  
284 Ltd. (Aichi, Japan), has received financial support from Santen Pharmaceutical Co. Ltd.

285 and Johnson & Johnson Vision, Jacksonville, FL, USA), and holds patents on the  
286 noncontact meibography system used in the study (Japanese patent registration no.  
287 5281846, U.S. patent publication no. 2011-0273550A1, European patent publication no.  
288 2189108A1).

289 9. Kim S, Shin J, Lee JE. A randomised, prospective study of the effects of 3%  
290 diquafosol on ocular surface following cataract surgery. *Sci Rep.* 2021;11(1):9124. Epub  
291 2021/04/29. doi: 10.1038/s41598-021-88589-7. PubMed PMID: 33907267; PubMed  
292 Central PMCID: PMCPMC8079705.

293 10. Endo KI, Sakamoto A, Fujisawa K. Diquafosol tetrasodium elicits total  
294 cholesterol release from rabbit meibomian gland cells via P2Y(2) purinergic receptor  
295 signalling. *Sci Rep.* 2021;11(1):6989. Epub 2021/03/28. doi: 10.1038/s41598-021-  
296 86433-6. PubMed PMID: 33772064; PubMed Central PMCID: PMCPMC7997929  
297 conflicts of interest in this work.

298 11. Zhang Q, Zhang H, Qin G, Wu Y, Song Y, Yang L, et al. Impact of Diquafosol  
299 Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Diabetic Dry Eye:  
300 A Pilot Study. *J Ocul Pharmacol Ther.* 2022;38(2):133-40. Epub 2022/01/21. doi:  
301 10.1089/jop.2021.0083. PubMed PMID: 35049373.

- 302 12. Qin G, Chen J, Li L, Qi Y, Chen Y, Zhang Q, et al. Effects of Diquafosol Sodium  
303 Ophthalmic Solution on Tear Film Matrix Metalloproteinase-9 and Corneal Nerve Density  
304 in Patients with Type 2 Diabetic Dry Eye. *J Ocul Pharmacol Ther.* 2023. Epub 2023/12/15.  
305 doi: 10.1089/jop.2023.0098. PubMed PMID: 38100078.
- 306 13. Uchino M, Yokoi N, Shimazaki J, Hori Y, Tsubota K, On Behalf Of The Japan  
307 Dry Eye S. Adherence to Eye Drops Usage in Dry Eye Patients and Reasons for Non-  
308 Compliance: A Web-Based Survey. *J Clin Med.* 2022;11(2). Epub 2022/01/22. doi:  
309 10.3390/jcm11020367. PubMed PMID: 35054060; PubMed Central PMCID:  
310 PMC8779746.
- 311 14. Hori Y, Oka K, Inai M. Efficacy and Safety of the Long-Acting Diquafosol  
312 Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked,  
313 Placebo-Controlled Phase 3 Study. *Adv Ther.* 2022;39(8):3654-67. Epub 2022/06/19.  
314 doi: 10.1007/s12325-022-02194-2. PubMed PMID: 35716319; PubMed Central PMCID:  
315 PMC9309120.
- 316 15. Ishikawa S, Sasaki T, Maruyama T, Murayama K, Shinoda K. Effectiveness and  
317 Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol  
318 Ophthalmic Solution. *J Clin Med.* 2023;12(13). Epub 2023/07/14. doi:

- 319 10.3390/jcm12134495. PubMed PMID: 37445527; PubMed Central PMCID:  
320 PMCPMC10342394.
- 321 16. Kaido M, Arita R. Effects of a Long-Acting Diquafosol Ophthalmic Solution on  
322 the Ocular Surface, Tolerability, and Usability in Dry Eye Disease. *Adv Ther.* 2024. Epub  
323 2024/05/06. doi: 10.1007/s12325-024-02871-4. PubMed PMID: 38709396.
- 324 17. Singh S, Srivastav S, Modiwala Z, Ali MH, Basu S. Repeatability,  
325 reproducibility and agreement between three different diagnostic imaging platforms for  
326 tear film evaluation of normal and dry eye disease. *Eye.* 2023;37(10):2042-7. Epub  
327 2022/10/20. doi: 10.1038/s41433-022-02281-2. PubMed PMID: 36261494; PubMed  
328 Central PMCID: PMCPMC10333265.
- 329 18. Rinert J, Branger G, Bachmann LM, Pfaeffli O, Iselin K, Kaufmann C, et al.  
330 Accuracy of a New Noninvasive Automatic Ocular Surface Analyzer for the Diagnosis  
331 of Dry Eye Disease-Two-Gate Design Using Healthy Controls. *Cornea.* 2023;42(4):416-  
332 22. Epub 2022/05/12. doi: 10.1097/ICO.0000000000003052. PubMed PMID: 35543570.
- 333 19. Arita R, Minoura I, Morishige N, Shirakawa R, Fukuoka S, Asai K, et al.  
334 Development of Definitive and Reliable Grading Scales for Meibomian Gland  
335 Dysfunction. *American journal of ophthalmology.* 2016;169:125-37. doi:  
336 10.1016/j.ajo.2016.06.025. PubMed PMID: 27345733.

- 337 20. van Bijsterveld OP. Diagnostic tests in the Sicca syndrome. Archives of  
338 ophthalmology. 1969;82(1):10-4. PubMed PMID: 4183019.
- 339 21. Shimazaki J, Sakata M, Tsubota K. Ocular surface changes and discomfort in  
340 patients with meibomian gland dysfunction. Archives of ophthalmology.  
341 1995;113(10):1266-70. PubMed PMID: 7575257.
- 342 22. Arita R, Itoh K, Inoue K, Amano S. Noncontact infrared meibography to  
343 document age-related changes of the meibomian glands in a normal population.  
344 Ophthalmology. 2008;115(5):911-5. Epub 2008/05/03. doi:  
345 10.1016/j.ophttha.2007.06.031. PubMed PMID: 18452765.
- 346 23. Shirmer O. Studien zur Physiologie und Pathologie der Tranenabsonderung und  
347 Tranenabfuhr. von Graefes Arch Ophthalmol. 1903;56:197-291.
- 348 24. Arita R, Suehiro J, Haraguchi T, Maeda S, Maeda K, Tokoro H, et al. Topical  
349 diquafosol for patients with obstructive meibomian gland dysfunction. The British journal  
350 of ophthalmology. 2013;97(6):725-9. doi: 10.1136/bjophthalmol-2012-302668. PubMed  
351 PMID: 23584719; PubMed Central PMCID: PMC3664386.
- 352 25. Wang Y, Dogru M, Matsumoto Y, Ward SK, Ayako I, Hu Y, et al. The impact  
353 of nasal conjunctivochalasis on tear functions and ocular surface findings. American

354 journal of ophthalmology. 2007;144(6):930-7. Epub 2007/10/06. doi:

355 10.1016/j.ajo.2007.07.037. PubMed PMID: 17916317.

356 26. Kimura N, Watanabe A, Suzuki K, Toyoda H, Hakamata N, Nakamura Y, et al.

357 [Measurement of age-related changes in human blinks using a high-speed blink analysis

358 system]. Nippon Ganka Gakkai Zasshi. 2012;116(9):862-8. Epub 2012/10/25. PubMed

359 PMID: 23092093.

360 27. Asbell PA, Maguire MG, Peskin E, Bunya VY, Kuklinski EJ, Dry Eye A, et al.

361 Dry Eye Assessment and Management (DREAM(c)) Study: Study design and baseline

362 characteristics. Contemp Clin Trials. 2018;71:70-9. Epub 2018/06/09. doi:

363 10.1016/j.cct.2018.06.002. PubMed PMID: 29883769; PubMed Central PMCID:

364 PMCPMC7250048.

365 28. Zhao M, Yu Y, Ying GS, Asbell PA, Bunya VY, Dry Eye A, et al. Age

366 Associations with Dry Eye Clinical Signs and Symptoms in the Dry Eye Assessment and

367 Management (DREAM) Study. Ophthalmol Sci. 2023;3(2):100270. Epub 2023/02/28.

368 doi: 10.1016/j.xops.2023.100270. PubMed PMID: 36846104; PubMed Central PMCID:

369 PMCPMC9950493.

370